About candel therapeutics inc - CADL
Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.
CADL At a Glance
Candel Therapeutics, Inc.
117 Kendrick Street
Needham, Massachusetts 02494
| Phone | 1-617-916-5445 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -38,182,000.00 | |
| Sector | Health Technology | Employees | 55 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
CADL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 5.987 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -4.819 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.215 |
CADL Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -694,218.182 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
CADL Liquidity
| Current Ratio | 13.492 |
| Quick Ratio | 13.492 |
| Cash Ratio | 13.308 |
CADL Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -32.806 |
| Return on Equity | -64.579 |
| Return on Total Capital | -37.82 |
| Return on Invested Capital | -44.96 |
CADL Capital Structure
| Total Debt to Total Equity | 94.438 |
| Total Debt to Total Capital | 48.57 |
| Total Debt to Total Assets | 39.03 |
| Long-Term Debt to Equity | 93.581 |
| Long-Term Debt to Total Capital | 48.129 |